Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
GSK plc stock logo
GSK
GSK
$40.88
-0.9%
$41.86
$33.33
$43.84
$85.47B0.642.84 million shs1.82 million shs
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$732.20
-1.8%
$763.40
$370.68
$800.78
$708.53B0.342.30 million shs2.05 million shs
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$126.20
-1.9%
$126.72
$75.56
$138.28
$577.28B0.413.36 million shs3.14 million shs
7 Stocks to Buy And Hold Forever Cover

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
GSK plc stock logo
GSK
GSK
-0.87%+3.23%-4.55%+5.25%+10.76%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
-1.80%-2.49%-5.24%+16.64%+90.26%
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
-1.88%+1.32%-2.21%+19.42%+199.44%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
GSK plc stock logo
GSK
GSK
2.3427 of 5 stars
0.03.03.30.01.80.02.5
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
4.8418 of 5 stars
2.44.02.54.02.52.53.1
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
3.0629 of 5 stars
1.45.02.50.03.20.03.1

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
GSK plc stock logo
GSK
GSK
2.40
HoldN/AN/A
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
2.84
Moderate Buy$728.05-0.57% Downside
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
2.75
Moderate Buy$133.605.86% Upside

Current Analyst Ratings

Latest LLY, NVO, and GSK Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/18/2024
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$160.00
4/15/2024
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$815.00
4/12/2024
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$163.00
4/11/2024
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$650.00 ➝ $723.00
4/3/2024
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Erste Group Bank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Buy
4/2/2024
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$675.00 ➝ $895.00
4/1/2024
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$815.00
4/1/2024
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$160.00
3/22/2024
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$850.00
3/20/2024
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$160.00
3/15/2024
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$775.00 ➝ $850.00
(Data available from 4/25/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
GSK plc stock logo
GSK
GSK
$37.71B2.25$5.14 per share7.95$7.74 per share5.28
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$34.12B20.39$7.49 per share97.78$11.44 per share64.00
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$33.71B16.80$2.95 per share42.72$3.45 per share36.58

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
GSK plc stock logo
GSK
GSK
$6.13B$3.0113.589.231.4516.24%51.45%10.57%5/1/2024 (Confirmed)
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$5.24B$5.80126.2439.581.6315.36%51.22%9.94%4/30/2024 (Confirmed)
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$12.15B$2.7146.6530.862.1536.03%90.36%29.18%5/2/2024 (Confirmed)

Latest LLY, NVO, and GSK Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/2/2024N/A
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$0.77N/A-$0.77N/AN/AN/A  
5/1/2024N/A
GSK plc stock logo
GSK
GSK
$0.95N/A-$0.95N/AN/AN/A
4/30/2024N/A
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$2.61N/A-$2.61N/AN/AN/A  
2/6/202412/31/2023
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$2.30$2.49+$0.19$2.56$8.95 billion$9.35 billion    
1/31/2024Q4 2023
GSK plc stock logo
GSK
GSK
$0.76$0.72-$0.04$1.23$9.79 billion$10.00 billion
1/31/2024Q4 2023
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$0.66$0.71+$0.05$0.71$9.14 billion$9.51 billion

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
GSK plc stock logo
GSK
GSK
$1.593.89%-18.20%52.82%1 Years
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$5.200.71%+15.15%89.66%10 Years
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$1.331.05%+16.52%49.17%1 Years

Latest LLY, NVO, and GSK Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
2/1/2024
GSK plc stock logo
GSK
GSK
quarterly$0.35643.4%2/22/20242/23/20244/11/2024
1/31/2024
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
Semi-Annual$0.66400.9%3/22/20243/25/20244/2/2024
(Data available from 1/1/2013 forward)

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
GSK plc stock logo
GSK
GSK
1.19
0.88
0.62
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
1.69
0.94
0.73
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
0.19
0.82
0.64

Ownership

Institutional Ownership

CompanyInstitutional Ownership
GSK plc stock logo
GSK
GSK
15.74%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
82.53%
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
11.54%

Insider Ownership

CompanyInsider Ownership
GSK plc stock logo
GSK
GSK
10.00%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
0.13%
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
0.07%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
GSK plc stock logo
GSK
GSK
70,2002.07 billion1.87 billionOptionable
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
43,000950.16 million948.93 millionOptionable
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
63,3704.49 billion4.48 billionOptionable

LLY, NVO, and GSK Headlines

SourceHeadline
Novo Nordisk A/S (NVO) to Release Earnings on ThursdayNovo Nordisk A/S (NVO) to Release Earnings on Thursday
americanbankingnews.com - April 25 at 4:46 AM
Wynn Capital LLC Invests $749,000 in Novo Nordisk A/S (NYSE:NVO)Wynn Capital LLC Invests $749,000 in Novo Nordisk A/S (NYSE:NVO)
marketbeat.com - April 24 at 6:56 PM
Novo Nordisk (NVO) Stock Sinks As Market Gains: Heres WhyNovo Nordisk (NVO) Stock Sinks As Market Gains: Here's Why
zacks.com - April 24 at 6:51 PM
Novo Nordisk A/S (NYSE:NVO) Trading Down 2.1%Novo Nordisk A/S (NYSE:NVO) Trading Down 2.1%
marketbeat.com - April 24 at 4:22 PM
Senate launches investigation into high prices of Ozempic and Wegovy in the U.S.Senate launches investigation into high prices of Ozempic and Wegovy in the U.S.
cnbc.com - April 24 at 3:22 PM
US Senate committee investigates pricing of Novos Ozempic and WegovyUS Senate committee investigates pricing of Novo's Ozempic and Wegovy
reuters.com - April 24 at 2:37 PM
3 Biotech Stocks With Skyrocketing Potential: April 20243 Biotech Stocks With Skyrocketing Potential: April 2024
investorplace.com - April 24 at 11:36 AM
4 Large Drug Stocks to Hold on to Amid Industry Challenges4 Large Drug Stocks to Hold on to Amid Industry Challenges
zacks.com - April 24 at 11:11 AM
Novo Nordisk A/S - Articles of Association, April 2024Novo Nordisk A/S - Articles of Association, April 2024
globenewswire.com - April 24 at 8:57 AM
Novo Nordisk A/S – Reduction of the share capitalNovo Nordisk A/S – Reduction of the share capital
globenewswire.com - April 24 at 8:48 AM
Missed Out on Novo Nordisk? 2 Healthcare Stocks With Big Catalysts on the Horizon.Missed Out on Novo Nordisk? 2 Healthcare Stocks With Big Catalysts on the Horizon.
fool.com - April 24 at 5:50 AM
Schnieders Capital Management LLC Boosts Position in Novo Nordisk A/S (NYSE:NVO)Schnieders Capital Management LLC Boosts Position in Novo Nordisk A/S (NYSE:NVO)
marketbeat.com - April 23 at 11:25 PM
Novo Nordisk A/S (NYSE:NVO) Stock Price Up 2.1%Novo Nordisk A/S (NYSE:NVO) Stock Price Up 2.1%
marketbeat.com - April 23 at 2:58 PM
Novo Nordisk (NVO) Boasts Earnings & Price Momentum: Should You Buy?Novo Nordisk (NVO) Boasts Earnings & Price Momentum: Should You Buy?
zacks.com - April 23 at 10:31 AM
Why Novo Nordisk Topped the Market TodayWhy Novo Nordisk Topped the Market Today
fool.com - April 22 at 6:08 PM
RWA Wealth Partners LLC Acquires 72,924 Shares of Novo Nordisk A/S (NYSE:NVO)RWA Wealth Partners LLC Acquires 72,924 Shares of Novo Nordisk A/S (NYSE:NVO)
marketbeat.com - April 22 at 3:46 PM
Novo Nordisk A/S (NYSE:NVO) Stock Price Up 1.7%Novo Nordisk A/S (NYSE:NVO) Stock Price Up 1.7%
marketbeat.com - April 22 at 2:32 PM
Changing Frugal Eating Habits - How Novo Nordisk/Eli Lillys Weight Loss Drugs Reshaping Food SpendingChanging Frugal Eating Habits - How Novo Nordisk/Eli Lilly's Weight Loss Drugs Reshaping Food Spending
msn.com - April 22 at 2:31 PM
Novo Nordisk A/S - share repurchase programmeNovo Nordisk A/S - share repurchase programme
globenewswire.com - April 22 at 9:06 AM
Wegovy vs. Zepbound: Who Wins the Battle of the GLP-1 Drugs?Wegovy vs. Zepbound: Who Wins the Battle of the GLP-1 Drugs?
marketbeat.com - April 22 at 6:05 AM
Wegovy vs. Zepbound: Who Wins the Battle of the GLP-1 Drugs?Wegovy vs. Zepbound: Who Wins the Battle of the GLP-1 Drugs?
marketbeat.com - April 22 at 6:05 AM
Shikiar Asset Management Inc. Has $13.14 Million Stock Position in Novo Nordisk A/S (NYSE:NVO)Shikiar Asset Management Inc. Has $13.14 Million Stock Position in Novo Nordisk A/S (NYSE:NVO)
marketbeat.com - April 21 at 4:51 PM
Novo Nordisk A/S (NYSE:NVO) Trading Up 0.5%Novo Nordisk A/S (NYSE:NVO) Trading Up 0.5%
americanbankingnews.com - April 21 at 3:56 AM
Riggs Asset Managment Co. Inc. Takes $4.79 Million Position in Novo Nordisk A/S (NYSE:NVO)Riggs Asset Managment Co. Inc. Takes $4.79 Million Position in Novo Nordisk A/S (NYSE:NVO)
marketbeat.com - April 20 at 5:36 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

GSK logo

GSK

NYSE:GSK
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.
Eli Lilly and Company logo

Eli Lilly and Company

NYSE:LLY
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Novo Nordisk A/S logo

Novo Nordisk A/S

NYSE:NVO
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with Aspen Pharmaceuticals to produce insulin products. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.